B. Riley Has Lowered Expectations for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price target decreased by investment analysts at B. Riley from $4.00 to $3.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley’s price target would indicate a potential upside of 476.92% from the company’s current price. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2027 earnings at ($0.08) EPS.

LCTX has been the subject of a number of other reports. Maxim Group decreased their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Finally, D. Boral Capital restated a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $4.20.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $0.52 on Friday. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61. The company has a market cap of $114.62 million, a price-to-earnings ratio of -4.33 and a beta of 1.21. The stock’s fifty day moving average is $0.60.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of institutional investors have recently added to or reduced their stakes in LCTX. Defender Capital LLC. boosted its stake in Lineage Cell Therapeutics by 19.2% in the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock valued at $2,997,000 after buying an additional 961,150 shares in the last quarter. Raffles Associates LP grew its holdings in Lineage Cell Therapeutics by 21.8% during the 4th quarter. Raffles Associates LP now owns 5,492,088 shares of the company’s stock worth $2,760,000 after acquiring an additional 984,307 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Lineage Cell Therapeutics during the fourth quarter worth approximately $1,984,000. Geode Capital Management LLC boosted its position in Lineage Cell Therapeutics by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after buying an additional 83,274 shares during the last quarter. Finally, State Street Corp increased its position in Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after purchasing an additional 45,483 shares during the period. 62.47% of the stock is owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.